Ping Zhan1, Ya-Nan Ji2, Li-Ke Yu3. 1. First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China; ; The Collaborative Research (CORE) Group, Sydney, Australia; 2. Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China. 3. First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China;
Abstract
BACKGROUND: Various studies examined the relationship between p53 mutation with the clinical outcome in patients with hepatocellular carcinoma (HCC), but yielded conflicting results. METHODS: Electronic databases updated to July 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between p53 mutation and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed. RESULTS: We performed a meta-analysis of 9 studies that evaluated the correlation between p53 mutation and survival in patients with HCC. Combined hazard ratios suggested that p53 mutation had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.46, 95% confidence interval (CI): 1.15-1.76], and disease free survival (DFS) (HR =2.57, 95% CI: 1.46-3.68) in patients with HCC. The significant heterogeneity (P=0.035) was observed among 8 studies for OS, however no significant heterogeneity (P=0.597) was observed among 5 studies for DFS. CONCLUSIONS: p53 mutation indicates a poor prognosis for patients with hepatocellular carcinoma.
BACKGROUND: Various studies examined the relationship between p53 mutation with the clinical outcome in patients with hepatocellular carcinoma (HCC), but yielded conflicting results. METHODS: Electronic databases updated to July 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between p53 mutation and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed. RESULTS: We performed a meta-analysis of 9 studies that evaluated the correlation between p53 mutation and survival in patients with HCC. Combined hazard ratios suggested that p53 mutation had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.46, 95% confidence interval (CI): 1.15-1.76], and disease free survival (DFS) (HR =2.57, 95% CI: 1.46-3.68) in patients with HCC. The significant heterogeneity (P=0.035) was observed among 8 studies for OS, however no significant heterogeneity (P=0.597) was observed among 5 studies for DFS. CONCLUSIONS:p53 mutation indicates a poor prognosis for patients with hepatocellular carcinoma.
Authors: Hang Su; Jing Zhao; Yujuan Xiong; Teng Xu; Fan Zhou; Yunfei Yuan; Ying Zhang; Shi-Mei Zhuang Journal: Mutat Res Date: 2008-02-14 Impact factor: 2.433
Authors: Yock Ping Chow; Lu Ping Tan; San Jiun Chai; Norazlin Abdul Aziz; Siew Woh Choo; Paul Vey Hong Lim; Rajadurai Pathmanathan; Noor Kaslina Mohd Kornain; Chee Lun Lum; Kin Choo Pua; Yoke Yeow Yap; Tee Yong Tan; Soo Hwang Teo; Alan Soo-Beng Khoo; Vyomesh Patel Journal: Sci Rep Date: 2017-03-03 Impact factor: 4.379
Authors: Jianwen Hao; Qizhen Peng; Keruo Wang; Ge Yu; Yi Pan; Xiaoling Du; Na Hu; Xuening Zhang; Yu Qin; Huikai Li Journal: Biomed Res Int Date: 2021-07-22 Impact factor: 3.411